Prognostic value of CEA and CA19-9 in patients with local advanced rectal cancer receiving neoadjuvant chemoradiotherapy, radical surgery and postoperative chemotherapy
| Autor: | Benxing Gu, Xiaonan Sun, Jingjing Shan, Weiwen Zhou, Liming Shi, Wenyuan Ye, Xuanxuan Wang |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Cancer Research
medicine.medical_specialty endocrine system diseases Postoperative chemotherapy business.industry Colorectal cancer Carbohydrate antigen 19-9 (CA19-9) medicine.disease digestive system diseases Oncology neoadjuvant chemoradiotherapy (neo-CRT) medicine Original Article Radiology Nuclear Medicine and imaging CA19-9 In patient prognosis Radiology carcinoembryonic antigen (CEA) Radical surgery rectal cancer business Value (mathematics) Neoadjuvant chemoradiotherapy |
| Zdroj: | Translational Cancer Research |
| ISSN: | 2219-6803 2218-676X |
| Popis: | Background We aim to investigate the prognostic factors and evaluate the role of carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) in local advanced rectal cancer (LARC) patients who received neoadjuvant chemoradiotherapy (neo-CRT), radical surgery and postoperative chemotherapy. Methods In total, 197 cases of LARC patients who underwent neo-CRT, total mesorectal excision (TME), and adjuvant chemotherapy were recruited. Serum levels of CEA and CA19-9 were detected both at baseline and after neo-chemoradiotherapy. Multivariate analysis was used to assess correlations between levels of CEA and CA19-9 and patients’ prognosis (survival, recurrence, and metastasis). Rates of survival, distant metastasis (DM), and local recurrence (LR) were estimated using Kaplan-Meier survival analysis, the log-rank test, and Cox proportional hazards. Results The median follow-up time was 45.3 months, and a cohort of 197 patients was analyzed; 84 (42.6%) patients had elevated baseline CEA levels, 21 (10.7%) patients had elevated baseline CA19-9 levels, and 14 (7.1%) patients had both; 77.4% (65/84) patients with high CEA levels and 76.2% (16/21) with high CA19-9 levels returned to normal after neo-chemoradiotherapy. The Cox regression model suggested that elevated CEA was associated with an increased risk of disease-free survival (DFS) (HR: 2.058, 95% CI: 1.034–4.096, P=0.040) and DM (HR: 2.144, 95% CI: 1.058–4.346, P=0.034). Elevated CA19-9 was identified as an independent prognostic factor, with poorer overall survival (OS) (HR: 2.894, 95% CI: 1.196–7.006, P=0.018) and DFS (HR: 4.533, 95% CI: 2.067–9.940, P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|